Buchumschlag

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is a clinically and histologically heterogeneous disorder. Its classification as either reactive inflammatory or neoplastic has been a matter of debate. However, the recent finding of frequent BRAFV600E mutations in LCH argues for the latter. The exact cell type t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sahm, Felix (VerfasserIn) , Capper, David (VerfasserIn) , Preusser, Matthias (VerfasserIn) , Meyer, Jochen (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Lasitschka, Felix (VerfasserIn) , Bergmeister-Berghoff, Anna Sophie (VerfasserIn) , Habel, Antje (VerfasserIn) , Kulozik, Andreas (VerfasserIn) , Anagnostopoulos, Ioannis (VerfasserIn) , Mechtersheimer, Gunhild (VerfasserIn) , Deimling, Andreas von (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Blood
Year: 2012, Jahrgang: 120, Heft: 12, Pages: e28-e34
ISSN:1528-0020
DOI:10.1182/blood-2012-06-429597
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1182/blood-2012-06-429597
Verlag, kostenfrei, Volltext: http://www.bloodjournal.org/content/120/12/e28
Volltext
Verfasserangaben:Felix Sahm, David Capper, Matthias Preusser, Jochen Meyer, Albrecht Stenzinger, Felix Lasitschka, Anna-Sophie Berghoff, Antje Habel, Marion Schneider, Andreas Kulozik, Ioannis Anagnostopoulos, Leonhard Müllauer, Gunhild Mechtersheimer, and Andreas von Deimling
Beschreibung
Zusammenfassung:Langerhans cell histiocytosis (LCH) is a clinically and histologically heterogeneous disorder. Its classification as either reactive inflammatory or neoplastic has been a matter of debate. However, the recent finding of frequent BRAFV600E mutations in LCH argues for the latter. The exact cell type that harbors the mutation and is responsible for proliferation remains to be identified. We here apply a BRAFV600E mutation-specific antibody to detect the BRAF mutant cells in lesions from 89 patients with LCH. We found BRAFV600E mutations in 34 of 89 (38%) lesions. In lesions with the BRAFV600E mutation, the majority of cells coexpressing S-100 and CD1a harbored mutant BRAFV600E protein. These cells also expressed CD14 and CD36, whereas various fractions exhibited CD207. On the other hand, CD80 and CD86 expression was also present on BRAFV600E-positive cells. Thus, cells of variable maturation, exhibiting an immunohistochemical profile compatible either with myeloid cell or with dedifferentiated Langerhans cell antigens, carry the BRAFV600E mutation. In conclusion, we identify and characterize the neoplastic cells in LCH with BRAFV600E mutations by applying a mutation-specific marker and demonstrate feasibility for routine screening.
Beschreibung:Published online September 20, 2012
Gesehen am 13.06.2018
Beschreibung:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2012-06-429597

Ähnliche Einträge